JP2007507222A - 化学療法に対する応答を予測するための遺伝子発現マーカー - Google Patents

化学療法に対する応答を予測するための遺伝子発現マーカー Download PDF

Info

Publication number
JP2007507222A
JP2007507222A JP2006533426A JP2006533426A JP2007507222A JP 2007507222 A JP2007507222 A JP 2007507222A JP 2006533426 A JP2006533426 A JP 2006533426A JP 2006533426 A JP2006533426 A JP 2006533426A JP 2007507222 A JP2007507222 A JP 2007507222A
Authority
JP
Japan
Prior art keywords
expression
cancer
array
chemotherapy
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507222A5 (enExample
Inventor
ジョフリ ビー． ベーカー，
キャシー ディー． ミラー，
スティーブン シャク，
ジョージ ダブリュー． スレッジ，
シャロン イー． スーレ，
Original Assignee
ゲノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲノミック ヘルス， インコーポレイテッド filed Critical ゲノミック ヘルス， インコーポレイテッド
Publication of JP2007507222A publication Critical patent/JP2007507222A/ja
Publication of JP2007507222A5 publication Critical patent/JP2007507222A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006533426A 2003-05-28 2004-05-24 化学療法に対する応答を予測するための遺伝子発現マーカー Pending JP2007507222A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47397003P 2003-05-28 2003-05-28
PCT/US2004/016553 WO2004111603A2 (en) 2003-05-28 2004-05-24 Gene expression markers for predicting response to chemotherapy

Publications (2)

Publication Number Publication Date
JP2007507222A true JP2007507222A (ja) 2007-03-29
JP2007507222A5 JP2007507222A5 (enExample) 2007-06-14

Family

ID=33551472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533426A Pending JP2007507222A (ja) 2003-05-28 2004-05-24 化学療法に対する応答を予測するための遺伝子発現マーカー

Country Status (6)

Country Link
US (1) US20050064455A1 (enExample)
EP (1) EP1631689A2 (enExample)
JP (1) JP2007507222A (enExample)
AU (1) AU2004248120B2 (enExample)
CA (1) CA2527285A1 (enExample)
WO (1) WO2004111603A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール
JP2016508710A (ja) * 2012-12-03 2016-03-24 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005039382A2 (en) 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
CA2604549A1 (en) 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
ES2404066T3 (es) * 2005-09-21 2013-05-23 Epigenomics Ag Marcadores para la predicción del resultado de un tratamiento con antraciclina
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
EP1994412A2 (en) * 2006-03-31 2008-11-26 Brystol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20100021424A1 (en) * 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
ES2427924T3 (es) * 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008098086A2 (en) * 2007-02-06 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2228457A1 (en) * 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2065475A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
EP2641978A1 (en) * 2008-05-12 2013-09-25 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP2806054A1 (en) * 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
GB0908467D0 (en) * 2009-05-15 2009-06-24 Univ Gent Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression
ES2351327B1 (es) * 2009-07-01 2011-11-28 Para La Investigacion Biomedica Del Hospital Universitario La Paz Fundacion Método de obtención de datos útiles para la predicción de respuesta clínica a un tratamiento de un paciente con cáncer.
ES2351328B1 (es) * 2009-07-10 2011-11-28 Para La Investigacion Biomedica Del Hospital Universitario La Paz Fundacion Método de obtención de datos útiles para la predicción de respuesta patológica a un tratamiento de un paciente con cáncer.
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011060537A1 (en) * 2009-11-20 2011-05-26 The Governors Of The University Of Alberta Predictive markers for taxane responsiveness and methods of use thereof
CN101760557B (zh) * 2010-03-04 2013-08-14 中国人民解放军军事医学科学院放射与辐射医学研究所 一种辅助诊断肝细胞癌的试剂盒
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013049666A1 (en) 2011-09-30 2013-04-04 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
EP2785873A4 (en) * 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
WO2013090620A1 (en) * 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
KR20150023904A (ko) 2012-06-27 2015-03-05 버그 엘엘씨 전립선암의 진단 및 치료에서의 마커의 용도
SI2880447T1 (sl) * 2012-07-31 2019-09-30 Novartis Ag Označevalci povezani z občutljivostjo na inhibitorje humanega dvominutnega 2 proteina (mdm2)
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9535055B2 (en) 2013-03-28 2017-01-03 Samsung Electronics Co., Ltd. Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
CN110444289A (zh) * 2013-06-28 2019-11-12 南托米克斯有限责任公司 用于诊断检测的识别的途径分析
HK1215453A1 (zh) * 2013-07-03 2016-08-26 豪夫迈．罗氏有限公司 用於将用mdm2拮抗剂进行患者癌症治疗个人化的基於mrna的基因表达
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
KR20150088433A (ko) 2014-01-24 2015-08-03 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
JP6742330B2 (ja) 2015-03-02 2020-08-19 サーコーティン ダイアグノスティックス エルエルシー 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現
WO2017075174A1 (en) * 2015-10-29 2017-05-04 The Research Foundation For The State University Of New York Keratin 17 as a prognostic marker for pancreatic cancer
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
GB201716712D0 (en) 2017-10-12 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Prognostic and treatment response predictive method
CN107808377B (zh) * 2017-10-31 2019-02-12 北京青燕祥云科技有限公司 一种肺叶中病灶的定位装置
US20220275458A1 (en) * 2019-08-07 2022-09-01 University Of Massachusetts Prediction of cancer therapy efficacy
EP4382911A1 (en) * 2022-12-07 2024-06-12 Oncomatryx Biopharma, S.L. Combining the expression levels of krt19 and col1a2 to produce a score for screening and diagnosing cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
CA2330929A1 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
WO2001051661A2 (en) * 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
WO2001055454A1 (en) * 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001075162A2 (en) * 2000-03-31 2001-10-11 University Of Louisville Research Foundation, Inc. Microarrays to screen regulatory genes
MXPA03000575A (es) * 2000-07-21 2004-12-13 Global Genomics Ab Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
EP1353947A2 (en) * 2000-12-08 2003-10-22 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
IL157872A0 (en) * 2001-03-12 2004-03-28 Monogen Inc A panel for detecting a generic disease state containing a plurality of probes and using cell-based diagnosis
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010038077, 医学のあゆみ， （２００２）， ２０３， ［３］， ｐ．１８９−１９０ *
JPN6010038078, Ｎａｔ． Ｍｅｄ．， （２００１）， ７， ［２］， ｐ．１９２−１９８ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2015165811A (ja) * 2007-10-05 2015-09-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2017060517A (ja) * 2007-10-05 2017-03-30 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2018126154A (ja) * 2007-10-05 2018-08-16 パシフィック エッジ リミテッド 胃腸癌での増殖の徴候及び予後
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール
JP2016508710A (ja) * 2012-12-03 2016-03-24 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価
US10460831B2 (en) 2012-12-03 2019-10-29 Koninklijke Philips N.V. Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab

Also Published As

Publication number Publication date
WO2004111603A3 (en) 2005-07-21
WO2004111603A2 (en) 2004-12-23
EP1631689A2 (en) 2006-03-08
AU2004248120B2 (en) 2009-04-23
CA2527285A1 (en) 2004-12-23
AU2004248120A1 (en) 2004-12-23
US20050064455A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
JP6190434B2 (ja) 化学療法剤に対する応答を予測するための遺伝子発現マーカー
AU2004248120B2 (en) Gene expression markers for predicting response to chemotherapy
JP4680898B2 (ja) 癌再発の可能性の予測
JP4723472B2 (ja) 乳癌予後診断のための遺伝子発現マーカー
JP5020088B2 (ja) 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
JP2007506442A (ja) Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
EP3556867A1 (en) Methods to predict clinical outcome of cancer
AU2011204944B2 (en) Gene expression markers for predicting response to chemotherapy
AU2017228579B2 (en) Prediction of likelihood of cancer recurrence
AU2016210735B2 (en) Gene expression markers for predicting response to chemotherapy
HK40014990A (en) Methods to predict clinical outcome of cancer
KR20070022694A (ko) 화학요법 반응을 예측하기 위한 유전자 발현 마커

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101201